In a new poll, consumers give thumbs up to ads that display drug prices and the removal of barriers to generics, among other cost-cutting measures.
The Senate Finance Committee grilled executives from seven major drugmakers on Tuesday.
Tuesday’s Senate Finance Committee hearing could produce fireworks over prices, R&D costs and executive compensation.
Tuesday’s Senate hearing with pharma CEOs will tackle the same issues as the famous Kefauver hearings in 1960.
Sen. Mike Enzi said he knew of a foundation that would import insulin for patients, but it doesn’t appear to exist.
President Donald Trump and FDA officials have pointed to a surge in generic drug approvals, but a data analysis indicates almost half haven’t reached the market.
The White House and HHS want to eliminate a “shadowy system of kickbacks” in the drug industry pipeline.
Patients are often forced into using brand names because drug formularies favor them over cheaper competitors.
Shereese Hickson’s doctor wanted her to try the infusion drug Ocrevus for her multiple sclerosis. Even though Hickson is trained as a medical billing coder, she was shocked to see two doses of the drug priced at $123,019, with her share set at $3,620.
Once viewed as a promising cost-control tool, such insurance faces new competition on benefits menus from more traditional insurance. But, according to new research, none of those choices is getting less expensive.
The Maryland Health Care Commission has created a consumer education campaign that puts the costs of common health care procedures on a place where people might see them – T-shirts.
Desperate for help in finding a lifesaving drug for a fatal genetic disease, families banded together to fund early research and then worked with drug companies on clinical trials and marketing. Yet, this small patient advocacy group is stunned by pharma’s pricing.
At least 11 states are going to try to tax opioids despite pushback from pharmaceutical companies.
Rep. Chris Collins talked one time too many, according to federal prosecutors who on Wednesday charged him with violating insider trading laws.
Grants by top pharma group to lightly regulated, politically active nonprofits dwarf its conventional campaign spending.
Several major drugmakers vow to contain drug prices, but similar pledges since the 1990s have not had much impact.
The Trump administration issued the final rule on association health plans, which supporters say will make coverage more affordable for some employees but led others to warn about “junk insurance.”
Promises to control pharma prices threaten profits for Switzerland-based Novartis, which sells some of the costliest drugs in the world.
Companies pushed proton machines and counted on advertising, doctors and insurers to ensure a steady business treating cancer. But the dollars haven’t flowed in as expected.
Denmark-based drugmaker Novo Nordisk has invested more in lobbying and doubled political donations since 2015.